// App-Quantinova.ai

: Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL): Initial Results of a Phase II Trial

Researchers

Presenter

  • Ryan D. Cassaday

Principal Investigators

  • Lorinda A. Soma

  • Olga Sala-Torra

  • Philip A. Stevenson

  • Mary-Elizabeth M. Percival

  • Vivian G. Oehler

  • Andrei R. Shustov

  • Pamela S. Becker

  • Anna B. Halpern

  • Kelsey-Leigh Garcia

  • Christen N. Heye

  • Jerald P. Radich

  • Elihu H. Estey

Medical Centers

  • Dept of Medicine, Univ of Washington, Seattle, WA

  • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

  • Seattle Cancer Care Alliance, Seattle, WA

  • Department of Laboratory Medicine, University of Washington, Seattle, WA

  • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

  • Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA

  • University of Washington, Seattle, WA

  • Division of Hematology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA

  • Department of Medicine/Division of Hematology, University of Washington, Seattle, WA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Lymphomas

  • Solid malignancies

Biomarkers

  • B-lymphocyte antigen CD20

  • Breakpoint Cluster Region

  • Granulocyte colony-stimulating factor

  • Hematocrit

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Vincristine

  • Doxorubicin

  • Prednisone

  • Etoposide

  • Etoposide phosphate

  • Rituximab

  • dasatinib

  • Imatinib

  • IkT001

  • Epoch

  • Filgrastim

Outcome

  • N/A

Study Design

  • Simon'S Two Stage Design

  • Single Center

Phase

  • II

Study Id's

  • NCT03023046

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved